Alzheimer's Drug Approval Pathway

How do FDA accelerated approvals differ from traditional approvals for Alzheimer’s drugs?

The FDA’s accelerated approval pathway lets Alzheimer’s drugs reach patients earlier by allowing approval on surrogate endpoints “reasonably likely” to predict benefit, with mandatory post‑marketing (...